Type of Assessment:
PIPAC for Malignant Peritoneal Mesothelioma: Current Insights and Future Directions
Digestive Surgery 2026 May 12 [Link] Arianna Castagna, Aphrodite Fotiadou, Ali Ramouz, Preslava Gesheva, Niall Brindl, Wiebke Solass, Andreas Brandl Abstract Malignant peritoneal mesothelioma (MPM) is a rare and aggressive tumour with poor prognosis, often diagnosed late due to nonspecific symptoms. Current standard treatment involves systemic chemotherapy and cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy…
Read MoreDiagnostic Challenges in Pleural Mesothelioma
Cancers 2026 April 25 [Link] Moshe Lapidot, Martin Sattler Abstract Accurate diagnosis of PM and precise histologic subtyping are critical for optimal therapeutic decision-making, as treatment strategies-including chemotherapy, immunotherapy, or multimodality approaches-are largely subtype-dependent. Because of the several-decade latency between fiber inhalation and symptom onset, many cases are diagnosed at an advanced stage, when patients…
Read MorePrognostic Significance of Inflammatory, Cellular, and Tumor-Specific Biomarkers in Patients With Pleural and Peritoneal Mesothelioma
Clinical Lung Cancer 2026 June [Link] Keval Yerigeri, Manjistha Sengupta, Jingli Zhang, Jeevan Puthiamadathil, Raffit Hassan Abstract Background: Mesothelioma is an aggressive malignancy with poor outcomes, particularly when diagnosed at advanced stages. This study evaluated the prognostic value of tumor-specific biomarkers: soluble mesothelin-related peptide (SMRP), megakaryocyte potentiating factor (MPF) and CA125; inflammatory markers: C-reactive protein…
Read MoreImpact of a national mesothelioma network on outcomes including survival
Thorax 2026 May 8 [Link] Matthew Tate, Joshua Joseph Roche, Selina Tsim, Neil McGlinchey, Katie Ferguson, Phil Reid, Philip Short, Mahendran Chetty, Clinton Ali, Noelle O’Rourke, Carol MacGregor, Carolyn MacRae, Laura McNaughton, Rebecca Bloomfield, Tracey Petrie, Susan Smyth, Jennifer Latham, Lynne Hunter, Rocco Bilancia, Alan Kirk, Craig Dick, Fiona Roberts, Elaine MacDuff, Jill Slavin, Hemamalini…
Read MoreReal-world outcomes of multimodal treatment for pleural mesothelioma: A retrospective study in a high-volume integrated regional center
JTCVS Open 2026 January 30 [Link] Alison S Baskin, Keza Levine, Yun-Yi Hung, Elaine Liang, Kian C Banks, J Marie Suga, Jeffrey B Velotta Abstract Objective: To evaluate overall survival (OS) associated with multimodal treatment regimens, including pleurectomy/decortication (PD) and systemic therapy, in patients with clinical stage I-II epithelioid pleural mesothelioma (PM). Methods: We identified…
Read MoreEpidermal growth factor receptor-targeted near-infrared photoimmunotherapy for malignant pleural mesothelioma
Lung Cancer 2026 July [Link] Miyu Kano, Aki Furusawa, Seiichiro Takao, Motofumi Suzuki, Makoto Kano, Hiroshi Yamamoto, Peter L Choyke, Hisataka Kobayashi Abstract Malignant pleural mesothelioma (MPM) is a rare, aggressive cancer mostly associated with asbestos exposure. Effective treatments are limited, and the prognosis is extremely poor. Therefore, the development of novel therapeutic approaches is…
Read MoreCellular Plasticity in Malignant Transformation: Mesothelial Cells
Pathobiology 2026 April 29 [Link] Claire W Michael, Ben Davidson Abstract Background: Mesothelial proliferations range from reactive lesions to benign and malignant tumors, bearing witness to the plasticity of these cells. Their diagnosis often requires combination of morphological assessment, immunohistochemistry, and molecular testing. Summary: Considerable progress has been made in recent years in all the…
Read MoreCellular Plasticity in Malignant Transformation: Mesothelial Cells
Pathobiology 2026 April 29 [Link] Claire W Michael, Ben Davidson Abstract Background: Mesothelial proliferations range from reactive lesions to benign and malignant tumors, bearing witness to the plasticity of these cells. Their diagnosis often requires combination of morphological assessment, immunohistochemistry, and molecular testing. Summary: Considerable progress has been made in recent years in all the…
Read MoreParaneoplastic Brachial Amyotrophic Diplegia and Encephalitis With Ma2-IgG During Immune Checkpoint Inhibitor Use for Mesothelioma: A Case Report
JTO Clinical and Research Reports 2026 March 6 [Link] Sanem Pinar Uysal, Shervin Badihian, Karlo Toljan, Nirmal Andrapalliyal, James Stevenson, Jonathan Lee, Amy Kunchok Abstract Background: Immune checkpoint inhibitors (ICIs) improve cancer survival but can cause neurologic immune-related adverse events. Ma2-IgG-associated paraneoplastic neurologic syndrome typically presents with central nervous system involvement in patients with testicular…
Read MoreImmunotherapy resistance and strategies in malignant pleural mesothelioma
Cancer Drug Resistance 2026 March 26 [Link] Wanyi Xia, Yulong Zhang, Juanzhi Zhao, Xiaoli Tan, Shaolong Ju, Wei Zou, Chaoqun Chen, Chunwei Li, Yanghua Xu, Yingming Peng, Shengqiao Li Abstract Malignant pleural mesothelioma (MPM) remains one of the most aggressive thoracic malignancies, characterized by profound resistance to conventional modalities such as surgery, chemotherapy, and radiotherapy,…
Read More
Skip to content